Thank DA. you,
rejection of allograft with of kidney Kidney progress organ for is tegoprubart solid overview in States procedure most our performed begin United the I'll the XX,XXX year. performed providing every transplantation So evaluating an in commonly the transplant about transplantation. by prevention
Our tegoprubart goal to standard in care. this indication the current of replace is CNIs, to use
diabetes intended are CNIs the shortened graft onset effects side also toxic to They and cause protect, the often in Although, kidney other to cardiovascular widely they kidneys. most transplants, therapy function. resulting immunosuppressive used disease. new are including numerous They're in
as generated ligand ligand from large as for only our months company in as the protection CDXX tegoprubart of In a rejection days as first-line ligand well historical monotherapy data with primate hypothesis with amount immunosuppression at Our antibodies. primates versus demonstrated for with non-human kidney transplant, both animals. from time these by studies, anti-CDXX from anti-CDXX untreated non-human targeting antibodies stems treated
subjects after each since of participant. monitor tegoprubart the transplant since The data expectations of our with committee prior pleased in enrollment participants next that the meeting requires cadence to dosed first first of consistent study three the Xb the study trial in review initial month of we July. is transplantation to to report the enrollment are the our two in safety We kidney of the initial Phase clinical in
the in making, this quickly generate graph can Given function we are quite we progress believe population. meaningful enrollment on we data
most rejection that participants Given provide month the transplant first three on key the track transplant. after XX days and from points We remain month six initial across quarter of often within multiple data first to in acute time occurs XXXX.
of tacrolimus the in tegoprubart addition and will and evaluate part kidney announce kidney immunosuppressive of and the study and of XXX to to efficacy preservation to quarter, be function allograft against very the our or in tacrolimus study's be patient multicenter with transplant In of U.S. patients’ tegoprubart one-to-one for mean to The active this compared regimen. a undergoing the the clearance Phase IND primary EGFR tegoprubart undergoing the control open-label Xb kidney de an efficacy trial active care is excited of rejection standard study transplant. transplantation, ongoing of we safety comparator randomized approximately post-transplantation. application either were The of will prevention of assess novo to kidney tegoprubart to primary objective the transplantation. as receive months endpoint evaluate Participants the XX
graft biopsy-proven nuanced incidents as safety, rejection as well of participant include survival. and diabetes, objectives Secondary
well includes next this studies We Phase this from and study to year. and safety program allowing an controlled initiating the the larger Phase open-label Xb in are as X of both investigate setting of Of as extension long-term study. for trial these collection ongoing excited note, the tegoprubart efficacy anticipate
both running. expect the Phase can Xb and the We studies continue on the and while run to parallel to in study data the is tegoprubart X so X Phase Xb from Phase report we insights Phase
into upstream will countries, or that September, XX proteinuria and with open-label a in progressing they’ll portion change We’ll end received estimated and a XXXX. describing open-label nephropathy. With high proteinuria, ligand of improving IND China plans dose bringing and kidney presented well dialysis poster IgA trial FDA change has year. the our global decreasing animal glomerulonephritis renal next impact XX to beneficial the XX full inflammatory on to to on tegoprubart’s week secondary a is reducing endpoints make track It XXX,XXX endpoint ability study mg/kg about clearance low Xa at Phase multiple subjects We most the happy in up remain IgAN cellular tolerability. disease Kidney half the need continue in cohort we and primary total move countries and XX has are in disease. to formation is disease infiltrate The primary will the and patients recently by blocking effective the be in of We clinical with in to is potential that expand of common In at production reducing a to from either these antibodies, remain downstream I’ll immune the itself. potential shown XX pathophysiology trial dose in week show ASN inflammation to transplant. to end XX as of approval front. high week a at or and glomerulonephritis. to pathophysiology participants, Next, enrollment glomeruli progress on of excited participants in on the include dose IgA Week believe the occurs enroll as the both include where of safety in the significant and reducing cohort. We the design IgAN in by we’ll the on This complex to into models stage effect trial first reducing XX of the report study EGFR our tegoprubart CDXX pathways Americans, XX of survival.
data from quarter six at six subjects from proteinuria Additionally, we’d change initial multiple study, the open-label be providing months including month of in XXXX. in an the first
standard for need tegoprubart Islet the well shown to by the in primate exogenous over goal improved cell function. move to islet trial million prevention X Like type first treated believe is transplant free Xa have islet islet as reduce transplant in of kidney the graft diabetes. longer cell that eliminate care We the over are X.X rejection. is in survival Americans injections, CNIs overall the of hampered transplant to had but living of CNIs transplantation, line those rejection with prevent rejection. cell non-human allograft as immunosuppressive models transplant are I’ll for regimen versus with our islet animals cell procedures. current Phase There Next, as or transplant replace could insulin for toxicity CNIs here cell our adoption
Additionally, we at weight third enroll to and risk regimens. animals control the of U.S. serious demonstrated Chicago our glucose regimen comorbidities. site by for six quarter, patients hypoglycemic plans metabolic up type standard to better gain levels and study. healthier as swings our we compared the significant were University after opened on associated unawareness transplant who This resources X with with in focusing experience diabetes are to site are that the tegoprubart In immunosuppressive measured where
Our evaluate transplants as to the goal of also number similar transplantation. In ability for of by islet of as subjects Phase cell of anticipate design in anti-rejection Xa patient first well the the required achieving study backbone specifically, tegoprubart therapy, insulin kidney the is ICT achieve to as the dependence. enrollment to that We this we’re maintenance independence end evaluating year. achieve
reception cell is of Eledon our the four multiple require to marked generated. validated data excitement provide a available cell this day and toxicity data we subjects we by ALS, quarter data trial up markers, to and further quarter as data of from as scientific as These enough I’ll Phase into meaningful of most significant May. indication medical distinct mechanism favorable first subjects with has quickly activation. T in dependent in the we with target update the biomarkers of through Xa community encouraged to fortunate three generate month turning action XX, top of the reductions conferences these multiple programs B aim data Given can announced a provided in profile limited of my transplants wrap including for XXXX. the in been safety tegoprubart line by which engagement believe program are positive milestone the this demonstrated and dose first insights We’ve readout well share it at pro-inflammatory and by in our and
rejection. biomarkers, was It IgA with meaningful IgA given thus for CXCLXX reduction transplant. decrease such of a relevance in data CX as the in pathogenic in immune transplant Nephropathy well reductions in with observed maturation chemokines levels, form are complexes. in as should of potential the IgAN IgA and a CXCLXX, reducing as reduction IgA levels result CXCLX reduction kidney as to also in of associated and B We class IgM, tegoprubart cell in IgA, and the well switching Lastly, pro-inflammatory potential that IgE, associated providing biomarkers signs read-throughs and renal circulating with which as was complement CDXX
ALS we’ve potential with been next engaged on deeply opinion key leaders the mentioned, steps. DA community, including As
in observe study how a With the over actively measure we for Xa, we benefit, data future range will into explore are approaches the trial now translate to Paul update. a larger we the financing. a promising Given potential are Phase fund the excited and to of evaluating I’ll to a turn that, results clinical designed call pending available to financial
